linjc16/ctgov huggingface dataset:
Chocolate's Effect on the Cerebral Vasculature

Study Overview
=================
Brief Summary
-----------------
The popularity of chocolate can largely be attributed to its mood elevating properties, research shows that it contains antioxidants that also provide physical health benefits. Dark chocolate, in particular, contains high levels of an antioxidant called epicatechin, which is known to cause changes in blood vessels by relaxing them and increasing blood flow. Little is know about the immediate effects of chocolate consumption, or the differences between milk and dark chocolate with regards to these effects. The project will investigate the effect of a single bar of dark or milk chocolate upon blood flow to the brain, using simple ultrasound tests.

Official Title
-----------------
A Randomised Trial of Effect of Chocolate Upon Cerebrovascular Reactivity in Healthy Adult Volunteers

Conditions
-----------------
Cerebral Vasculature

Intervention / Treatment
-----------------
* Other: cocoa


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No regular medication including vitamins/antioxidants Able to provide informed consent Exclusion Criteria: Inability to perform breath-hold test Any known cardiovascular disease, diabetes, throid disease, high blood pressure, hyperlipidaemia or pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 100 g containing 70% or 34% cocoa<br>Healthy controls | Other: cocoa<br>* 70% versus 34%<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Determine effect on cerebral vasculature
The Clinical Profile of Parkinson Disease in Egypt

Study Overview
=================
Brief Summary
-----------------
Multi-center, retrospective observational cohort study in 4 tertiary referral centers in Cairo over the period from 2004 to 2016. Study population. including all patients with idiopathic Parkinson disease attending. Patients were diagnosed in accordance to the United Kingdom - Parkinson Disease Society Brain Bank criteria.

Detailed Description
-----------------
Retrospective, observational study that involve Medical Record Review (MRR). Data extraction and collection from medical records was organized through an electronic structured data collection form by two of authors (H.S and N.S). The abstraction documents included; patient's age, sex, family history, age at onset, type and side of motor symptoms onset, associated non-motor manifestations. Moreover; management plan, drug history, outcome and disease progression were also verified and recorded. During medical record reviewing (MRR); any missing documentation or poorly recorded information was managed by deleting the case.

Official Title
-----------------
The Clinical Profile of Parkinson Disease in Egypt: A Retrospective Cohort Study

Conditions
-----------------
Parkinson's Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with Parkinsonian syndromes Exclusion Criteria: Records with missing operationalized variables from patient records

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Idiopathic Parkinson Disease<br> | |
| Other Parkinsonian syndromes<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to L-Dopa start | The time to L-Dopa start from symptoms onset in relation to time of Diagnosis | 6 - 12 months |
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Study Overview
=================
Brief Summary
-----------------
To evaluate the effectiveness and safety in randomized, double-blind, parallel-group study in anemic cancer patients undergoing chemotherapy

Official Title
-----------------
A Randomized, Double-Blind Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Conditions
-----------------
Chemotherapy Induced Anemia

Intervention / Treatment
-----------------
* Drug: recombinant human erythropoietin
* Drug: recombinant human erythropoietin placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cancer patients Exclusion Criteria: a history of myocardial, cerebral or pulmonary infarction severe hypertension beyond control by drugs

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: recombinant human erythropoietin<br>* 36000IU（0.5mL）s.c./week for 8 weeks<br>|
| Placebo Comparator: 2<br> | Drug: recombinant human erythropoietin placebo<br>* 0 IU(0.5mL)s.c./week for 8 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The increase in Hb concentration |  | week 8 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in QOL scores |  | 8 weeks |
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel in Gastric Cancer Patients With Peritoneal Metastasis

Study Overview
=================
Brief Summary
-----------------
This is a phase I trial investigating the safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) using paclitaxel combined with intravenous FOLFOX therapy for gastric cancer patients with peritoneal metastasis.

Official Title
-----------------
Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel in Gastric Cancer Patients With Peritoneal Metastasis

Conditions
-----------------
Stomach Neoplasm, Peritoneal Metastases

Intervention / Treatment
-----------------
* Procedure: Pressurized Intraperitoneal Aerosol Chemotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathologically diagnosed as gastric adenocarcinoma Imaging scans or diagnostic laparoscopic findings suggestive of peritoneal metastasis HER-2 negative tumor Laboratory tests adequate for chemotherapy (within 2 weeks of enrollment) Absolute Neutrophil Count: ≧ 1,500/mm³ Hemoglobin level: ≧ 8.0g/dL Platelet Count: ≧ 10×104/mm³ AST (GOT), ALT (GPT): ≦ 100U/L Total Bilirubin: ≦ 2.0mg/dL Creatinine Clearance (CCl): ≧ 50mL/min ECOG 0 - 2 Exclusion Criteria: Patients with other major medical disease or malignant tumors other than gastric cancer Contraindication to 5-FU, Oxaliplatin, Leukovorin or Paclitaxel Pregnant, breast-feeding women or with birth plan History of gastrointestinal surgery Patients refusing treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PIPAC Paclitaxel with FOLFOX<br>PIPAC (Paclitaxel) + Systemic mFOLFOX6(5-FU, Oxaliplatin, Leucovorin) | Procedure: Pressurized Intraperitoneal Aerosol Chemotherapy<br>* Aerosolization of chemotherapic agent for intraperitoneal chemotherapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recommended dose | Recommended dose of paclitaxel for a phase II trial | Dose-limiting toxicity within 2 weeks after 1st intraoperative PIPAC (each cycle is 6 weeks) |
Efficiency, Predictability and Security of the Trans-epithelial Photorefractive Keratectomy

Study Overview
=================
Brief Summary
-----------------
The photorefractive keratectomy was the first correction mode refractive laser. It's a photo-ablation of a predetermined thickness of anterior corneal stroma. Debridement of epithelium can be done either mechanically (m-PRK) or by laser (trans-PRK). Trans-PRK has a lot of interests: facility and speed of procedure as well as suppression of human variable. Very good results are obtained by m-PRK. The aim of this study is to show equivalence or non inferiority of trans-PRK over conventional m-PRK in terms of safety and refractive efficiency

Official Title
-----------------
Efficiency, Predictability and Security of the Trans-epithelial Photorefractive Keratectomy (Trans-PRK) for Low and Medium Myopia and Astigmatism: Retrospective Study About 118 Eyes

Conditions
-----------------
Myopia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with stable refractive error (more than 2 years) Myopia up to -4.00 diopters and astigmatism up to -3.00 diopters Exclusion Criteria: Phototherapeutic keratectomy (PTK)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| visual acuity | LogMar | Month 2 |
Exercise in Sjogren, Myositis and Takayasu's Arteritis

Study Overview
=================
Brief Summary
-----------------
Exercise may improve physical capacity and health parameters in Primary Syndrome´s Sjogren, Myositis and Takayasu's Arteritis. Therefore, this study aims to investigate the role of an exercise training program in patients with Primary Syndrome´s Sjogren, Myositis and Takayasu's Arteritis.

Official Title
-----------------
Effects of Exercise Training in Primary Sjogren´s Syndrome, Myositis and Takayasu's Arteritis

Conditions
-----------------
Primary Sjogren´s Syndrome, Myositis

Intervention / Treatment
-----------------
* Other: Exercise training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Physically inactive Stable drugs regime for at least three months Exclusion Criteria: Other rheumatic diseases Physical disability that prevent the patient to perform the physical tests Severe pulmonary disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Sjogren and Myositis Control (no control for takayasu's)<br> | |
| Experimental: Sjogren, Myositis and Takayasu's Trained<br> | Other: Exercise training<br>* Sjöegren arm: 30-60 minutes of combined aerobic and strength exercises, twice a week, moderate intensity. Myositis arm: 30 minutes of resistance training combined partial blood flow restriction, twice a week, low intensity. Takayasu's arteritis arm: 30-50 minutes of aerobic, twice a week, moderate intensity.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aerobic Capacity | Maximum Oxygen Consumption (VO2Max) | Twelve weeks | 
| Muscle strength |  | Twelve weeks | 
| Quality of life |  | Twelve weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum anti-inflammatory cytokines | Interleukin-10 | Twelve weeks | 
| Serum pro-inflammatory cytokines | Interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a) | Twelve weeks | 
| Serum inflammatory markers | erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), aldolase | Twelve weeks |
Clinical Study Between Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations

Study Overview
=================
Brief Summary
-----------------
A randomized, double-blind, multiple-site, placebo-controlled, parallel-group clinical study conducted to evaluate the bioequivalence of two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel formulations.

Official Title
-----------------
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled Study Comparing Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations in the Treatment of Moderate to Severe Acne Vulgaris

Conditions
-----------------
Acne Vulgaris

Intervention / Treatment
-----------------
* Drug: 1% Clindamycin/5% Benzoyl Peroxide Topical Gel
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy men or women, 12 years of age and older willing to participate and sign a copy of the informed consent form moderate to severe facial acne Exclusion Criteria: history of allergy or hypersensitivity to clindamycin or benzoyl peroxide pregnant or lactating women evidence of a clinically significant disorder receipt of any drugs as part of a research study within 30 days prior to study dosing use of systemic, topical or facial products which may interfere with study significant facial hair, tattoos, excessive facial scarring, active facial sunburn, or peeling due to sunburn

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1% Clindamycin/5% Benzoyl Peroxide Topical Gel<br>Test product | Drug: 1% Clindamycin/5% Benzoyl Peroxide Topical Gel<br>* Topical Gel<br>* Other names: DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel;|
| Active Comparator: DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel<br>Reference product | Drug: 1% Clindamycin/5% Benzoyl Peroxide Topical Gel<br>* Topical Gel<br>* Other names: DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel;|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of Inflammatory Lesions | The primary endpoint of the study was the mean percent reduction from baseline to week 11 in inflamed lesion count (papules and pustules). | Baseline and week 11 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acne Vulgaris, bioequivalency, clindamycin, benzoyl peroxide
Comparison of Cold and Hot Snare Resection for Colorectal Polyps Sized 10-19mm.

Study Overview
=================
Brief Summary
-----------------
Patients who met the criteria for removal of 10-19mm colorectal polyps using cold snare or hot snare were included in the study, signed by endoscopic treatment written informed consent for surgery, patients with detailed tracking and record the basic information and information related to the operation, postoperative lack of region and edge endoscopic observation carefully no residue, additional excision may be took if necessary，after resection specimen inspection, and in 6 months review colonoscopy, assess whether there is residual or recurrence of polyps.Main outcome: technical success rate (no other auxiliary resection), complete resection rate, secondary outcome: intraoperative and postoperative complications, polypectomy time and related costs, influential factors of incomplete resection.Research significance: The effectiveness, safety and cost-effectiveness of cold and hot snare resection of 10-19mm colorectal polyps were compared, and the influencing factors of incomplete polyps resection were analyzed, so as to provide evidence for the decision on the best method of medium-size polyps resection.

Official Title
-----------------
A Prospective Observational Study of Cold and Hot Snare Resection for Colorectal Polyps Sized 10-19mm.

Conditions
-----------------
Colonic Polyps/Colonoscopy/Colorectal Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: colorectal polyps sized 10≤ diameter ≤19 mm; Boston bowel prepare score: 5-9; The patients all signed the informed consent of endoscopic treatment. Exclusion Criteria: Complicated with inflammatory bowel disease, P-J syndrome or familial polyposis; Complicated with malignant tumors; polyp size is uncertain; Currently taking aspirin, warfarin or other anticoagulants.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CSP<br> | |
| HSP<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Technical success rate | (without other auxiliary resection) | 2020.07.31 | 
| Complete resection rate |  | 2021.01.31 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraoperative and postoperative complications |  | 2021.01.31 | 
| Polypectomy time |  | 2021.01.31 | 
| related costs of treatment |  | 2021.01.31 |
Immunological and Cardiovascular Phenotyping of Oocyte-donation Pregnancies

Study Overview
=================
Brief Summary
-----------------
The investigators conduct a study to evaluate the underlying causes of preeclampsia in oocyte-donation pregnancies.

Detailed Description
-----------------
A detailed medical history, questionnaires as well as blood, urine and placental samples will be used to analyse several factors leading to the high risk of preeclampsia in oocyte-donation pregnancies.

Official Title
-----------------
Immunological and Cardiovascular Phenotyping of Oocyte-donation Pregnancies

Conditions
-----------------
Preeclampsia, Oocyte-donation Pregnancies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnancy Exclusion Criteria: severe auto immune disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| healthy oocyte-donation pregnancy<br>healthy pregnancy | |
| preeclamptic oocyte-donation pregnancy<br>preeclampsia | |
| healthy IVF or ICSI pregnancy<br>healthy pregnancy | |
| preeclamptic IVF or ICSI pregnancy<br>preeclampsia | |
| healthy spontaneous conception pregnancy<br>healthy pregnancy | |
| preeclamptic spontaneous conception pregnancy<br>preeclampsia | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Preeclampsia in oocyte-donation pregnancies is caused by an altered composition of immune cells in placenta and blood. | T-Cell populations are altered in preeclampsia. HLA-mismatch of mother and donor oocyte lead to a host-versus-graft reaction. T-, B- and Natural killer cells are altered in placental tissue of oocyte-donation pregnancies. | 01.01.2020 - 01.12.2025 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Preeclampsia in oocyte-donation pregnancies is caused by an activation of pro-inflammatory factors and endothelial dysfunction. | Altered Natural killer cells and B-cells in oocyte-donation pregnancies lead to endothelial dysfunction. Pro-inflammatory factors are higher in OD pregnancy and can be measured in placental tissue via single-cell sequencing. | 01.01.2020 - 01.12.2025 |
Precision Immunology to Determine the Immune Response in Patients With COVID-19

Study Overview
=================
Brief Summary
-----------------
To better understand the immune response to SARS-CoV-2 infection, we devised a precision immunology approach to systematically study the immune function of different patient cohorts

Official Title
-----------------
Precision Immunology Approach to Better Understand the Divergent Host Responses Towards Infection With SARS-CoV-2

Conditions
-----------------
SARS-CoV 2, COVID

Intervention / Treatment
-----------------
* Other: Blood draw


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: SARS-Cov2 positive PCR Exclusion Criteria: pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| asymptomatic Covid-19<br>Patients with confirmed SARS-CoV2 PCR but no clinical symptoms | Other: Blood draw<br>* serial blood draw and subsequent deep immune phenotyping analysis, (ii.) immune activation assays, (iii.) transcriptome and (iv.) epigenome analysis in an overarching (v.) bioinformatics data analysis<br>|
| symptomatic Covid-19<br>Patients with confirmed SARS-CoV2 PCR and light clinical symptoms | Other: Blood draw<br>* serial blood draw and subsequent deep immune phenotyping analysis, (ii.) immune activation assays, (iii.) transcriptome and (iv.) epigenome analysis in an overarching (v.) bioinformatics data analysis<br>|
| severe Covid-19<br>Patients with confirmed SARS-CoV2 PCR and severe clinical symptoms with ICU admission | Other: Blood draw<br>* serial blood draw and subsequent deep immune phenotyping analysis, (ii.) immune activation assays, (iii.) transcriptome and (iv.) epigenome analysis in an overarching (v.) bioinformatics data analysis<br>|
| healthy controls<br>Persons with negative SARS-CoV2 PCR | Other: Blood draw<br>* serial blood draw and subsequent deep immune phenotyping analysis, (ii.) immune activation assays, (iii.) transcriptome and (iv.) epigenome analysis in an overarching (v.) bioinformatics data analysis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immune response | Immune response of whole blood stimulation assay with various immune activators will be measured by FACS and multiplex Assay | 4 weeks |